Brookline Capital Acquisition Weighs in on NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Acquisition issued their Q1 2026 EPS estimates for shares of Intellia Therapeutics in a report issued on Thursday, February 26th. Brookline Capital Acquisition analyst L. Cann anticipates that the company will earn ($0.85) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Acquisition also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.53) EPS, FY2028 earnings at $17.06 EPS and FY2029 earnings at $46.29 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The company had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. Intellia Therapeutics’s revenue was up 78.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.27) earnings per share.

Several other equities analysts have also weighed in on NTLA. Truist Financial reaffirmed a “buy” rating and issued a $14.00 price objective (down from $25.00) on shares of Intellia Therapeutics in a research note on Monday, November 10th. KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, January 28th. Citizens Jmp decreased their price objective on shares of Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Royal Bank Of Canada dropped their price objective on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Finally, Wells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.48.

Intellia Therapeutics Trading Up 6.4%

Shares of NTLA opened at $14.28 on Friday. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25. The firm has a market capitalization of $1.65 billion, a P/E ratio of -3.34 and a beta of 2.10. The stock’s fifty day simple moving average is $11.80 and its 200 day simple moving average is $13.00.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. Virtu Financial LLC acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at approximately $245,000. Invesco Ltd. raised its holdings in Intellia Therapeutics by 5.8% in the fourth quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after acquiring an additional 23,870 shares in the last quarter. Axxcess Wealth Management LLC boosted its stake in Intellia Therapeutics by 20.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after acquiring an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Intellia Therapeutics during the 4th quarter worth $90,000. Finally, XTX Topco Ltd bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $402,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Activity

In other news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP James Basta sold 10,397 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. This represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 53,051 shares of company stock worth $488,600. 3.10% of the stock is currently owned by company insiders.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 beat — Intellia reported a narrower-than-expected loss (EPS -$0.83 vs. -$0.99 est.) and revenue of $23.02M (well above estimates), with revenue up ~78% year-over-year; that earnings surprise is a key catalyst for the stock. Intellia Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: Strong cash runway — Intellia ended 2025 with approximately $605M in cash, providing runway to advance multiple programs and de-risk near-term milestones. This cash position supports R&D and commercial preparation. Q4 & Full-Year 2025 Financial Results
• Positive Sentiment: Clear near-term commercial path for lonvo‑z — Management guided to HAELO Phase 3 data by mid‑2026, a potential BLA submission in 2H‑2026 and U.S. launch in 1H‑2027, which could materially re-rate the company if successful. Business Updates & Timelines
• Neutral Sentiment: Management tone and strategic updates from the earnings call emphasized clinical progress, commercial readiness and long-term CRISPR strategy—helpful context but dependent on upcoming data and approvals. Earnings Call Transcript
• Negative Sentiment: Regulatory risk: an FDA clinical hold remains for the MAGNITUDE Phase 3 trial of nex‑z in ATTR‑CM; management is engaging FDA but resolution timing is uncertain and could delay or impair that program’s value. Earnings Call Highlights & Regulatory Update
• Negative Sentiment: Profitability risk: despite the quarter-over-quarter improvement, Intellia remains unprofitable with large negative margins and analyst forecasts calling for steep net losses ahead, leaving the stock sensitive to R&D setbacks or slower-than-expected commercial progress. Zacks Q4 Coverage

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.